New oral drug shows promise for Long-Term control of rare bleeding disorder

NCT ID NCT07216079

Ongoing Disease control Sponsor: Sanofi Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study is for adults with chronic immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, causing bleeding and bruising. It tests the long-term safety and benefit of an oral drug called rilzabrutinib. Only 4 participants who already benefited from the drug in a prior study will continue treatment. The goal is to see if the drug remains safe and effective over time.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: rilzabrutinib (oral tablet)
What this could lead to: If successful, this study could show that rilzabrutinib is a safe and effective long-term treatment option for managing chronic immune thrombocytopenia.
What could go wrong: This is a very small extension study (only 4 participants) with no placebo group, so results may not apply broadly. Long-term safety and effectiveness are still being evaluated.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for IMMUNE THROMBOCYTOPENIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

autoimmune thrombocytopenic purpura Purpura, Thrombocytopenic, Idiopathic thrombocytopenia due to immune destruction

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

IMMUNE THROMBOCYTOPENIA

Contacts and locations

Locations

Investigational Site Number: 1001

Tsuchiura, Ibaraki, 300-0028, Japan
Investigational Site Number: 1002

Kanazawa, Ishikawa-ken, 920-8641, Japan
Investigational Site Number: 1003

Iruma-gun, Saitama, 350-0495, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.